Objective: To describe sociodemographic and parent psychosocial characteristics associated with patterns of continuous glucose monitor (CGM) use across the first 18 months post-type 1 diabetes (T1D) diagnosis among young children. Methods: One hundred fifty-seven parent-child dyads enrolled in a behavioral intervention for parents of young children (1-6 years) newly diagnosed with T1D. Parents reported on baseline sociodemographic characteristics and psychosocial functioning; child CGM use was assessed at five time points during the first 18 months post-diagnosis. Results: Most participants (81.8%) used CGM at least once. Four CGM trajectories emerged (always, later/stable, inconsistent, and never). Participants with private insurance were more likely to be in the always, later/stable, or inconsistent groups versus the never group. Youth in the always and later/stable groups had lower mean HbA1c at 18 months than those in the never group. Conclusions: Given the health benefits of CGM, further exploration of barriers to CGM use in families with public health insurance is needed. ClinicalTrials.gov identifier: NCT02527525.
Objective: To describe sociodemographic and parent psychosocial characteristics associated with patterns of continuous glucose monitor (CGM) use across the first 18 months post-type 1 diabetes (T1D) diagnosis among young children. Methods: One hundred fifty-seven parent-child dyads enrolled in a behavioral intervention for parents of young children (1-6 years) newly diagnosed with T1D. Parents reported on baseline sociodemographic characteristics and psychosocial functioning; child CGM use was assessed at five time points during the first 18 months post-diagnosis. Results: Most participants (81.8%) used CGM at least once. Four CGM trajectories emerged (always, later/stable, inconsistent, and never). Participants with private insurance were more likely to be in the always, later/stable, or inconsistent groups versus the never group. Youth in the always and later/stable groups had lower mean HbA1c at 18 months than those in the never group. Conclusions: Given the health benefits of CGM, further exploration of barriers to CGM use in families with public health insurance is needed. ClinicalTrials.gov identifier: NCT02527525.
Entities:
Keywords:
Continuous glucose monitoring; Glycemic outcomes; Health insurance; Pediatrics
Authors: Steven M Willi; Kellee M Miller; Linda A DiMeglio; Georgeanna J Klingensmith; Jill H Simmons; William V Tamborlane; Kristen J Nadeau; Julie M Kittelsrud; Peter Huckfeldt; Roy W Beck; Terri H Lipman Journal: Pediatrics Date: 2015-03 Impact factor: 7.124
Authors: Persis V Commissariat; Claire T Boyle; Kellee M Miller; Manasa G Mantravadi; Daniel J DeSalvo; William V Tamborlane; Michelle A Van Name; Barbara J Anderson; Linda A DiMeglio; Lori M Laffel Journal: Diabetes Technol Ther Date: 2017-06-05 Impact factor: 6.118
Authors: Jessica T Markowitz; Katherine Pratt; Jyoti Aggarwal; Lisa K Volkening; Lori M B Laffel Journal: Diabetes Technol Ther Date: 2012-04-23 Impact factor: 6.118
Authors: Jenise C Wong; Nicole C Foster; David M Maahs; Dan Raghinaru; Richard M Bergenstal; Andrew J Ahmann; Anne L Peters; Bruce W Bode; Grazia Aleppo; Irl B Hirsch; Lora Kleis; H Peter Chase; Stephanie N DuBose; Kellee M Miller; Roy W Beck; Saleh Adi Journal: Diabetes Care Date: 2014-07-10 Impact factor: 19.112
Authors: Molly L Tanenbaum; Sarah J Hanes; Kellee M Miller; Diana Naranjo; Rachel Bensen; Korey K Hood Journal: Diabetes Care Date: 2016-11-29 Impact factor: 19.112
Authors: Ananta Addala; Marie Auzanneau; Kellee Miller; Werner Maier; Nicole Foster; Thomas Kapellen; Ashby Walker; Joachim Rosenbauer; David M Maahs; Reinhard W Holl Journal: Diabetes Care Date: 2020-09-16 Impact factor: 19.112